Tvardi Therapeutics Appoints New Directors and CMO

TL;DR

Tvardi adds new blood to board & exec team, watch compensation details.

AI Summary

Tvardi Therapeutics, Inc. announced on December 16, 2025, changes in its board of directors and executive compensation. Specifically, the company elected two new directors, Dr. Jonathan Lim and Mr. David J. E. Johnson, and appointed Mr. Michael J. McVicar as Chief Medical Officer. The filing also details compensatory arrangements for these individuals.

Why It Matters

The appointment of new leadership and changes in executive compensation can signal strategic shifts or a focus on specific growth areas for the company.

Risk Assessment

Risk Level: medium — Changes in board and executive roles, especially with new appointments, can introduce uncertainty or signal strategic pivots.

Key Players & Entities

• Tvardi Therapeutics, Inc. (company) — Registrant
• Dr. Jonathan Lim (person) — Newly elected director
• Mr. David J. E. Johnson (person) — Newly elected director
• Mr. Michael J. McVicar (person) — Appointed Chief Medical Officer
• Cara Therapeutics, Inc. (company) — Former company name

FAQ

Key Financial Figures

• $0.001 — registered Common Stock, par value $0.001 per share TVRD The Nasdaq Stock Marke

Filing Documents

• tm2533917d1_8k.htm (8-K) — 37KB
• 0001104659-25-122615.txt ( ) — 202KB
• tvrd-20251216.xsd (EX-101.SCH) — 3KB
• tvrd-20251216_lab.xml (EX-101.LAB) — 33KB
• tvrd-20251216_pre.xml (EX-101.PRE) — 22KB
• tm2533917d1_8k_htm.xml (XML) — 4KB

02. Departure of Directors or Certain Officers, Election

Item 5.02. Departure of Directors or Certain Officers, Election of Directors, Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Retention Compensation On December 16, 2025, the Board of Directors of Tvardi Therapeutics, Inc. (the "Company") approved one-time retention compensation for certain of the Company's employees, as recommended by the Compensation Committee of the Board, including to each of the Company's named executive officers, as follows: Name and Title Option to Purchase Shares (#) (1) Dr. Imran Alibhai, Chief Executive Officer 47,500 Dr. John Kauh, Chief Medical Officer 17,500 Dan Conn, Chief Financial Officer 17,500 (1) The per-share exercise price of the option equals the closing per-share price of the Company's common stock on the date of grant. 25% of the shares subject to the option will vest on the one-year anniversary of the vesting commencement date, which is December 16, 2026, and the balance of the shares will vest in a series of thirty-six (36) successive equal monthly installments measured from the first anniversary of the vesting commencement date. The Board approved the retention compensation to further incentivize the named executive officers' performance as the Company executes on its Phase 1b/2 clinical trial of TTI-101 in hepatocellular carcinoma and Phase 1 trial of TTI-109 in healthy volunteers. Tvardi Therapeutics, Inc. Severance and Change in Control Plan On December 16, 2025, the Board approved the Tvardi Therapeutics, Inc. Severance and Change in Control Plan (the "Severance Plan"), as recommended by the Compensation Committee of the Board. The purpose of the Severance Plan is to provide for the provision of certain severance and equity vesting acceleration benefits to certain employees of the Company (collectively, the "Eligible Employees"), including without limitation all of the Company's existing named executive officers. As a condition for eligibility, participants must en

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TVARDI THERAPEUTICS, INC. Date: December 18, 2025 By: /s/ Imran Alibhai Name: Imran Alibhai Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR